REFERENCES
1. Heusch G. Myocardial ischaemia-reperfusion injury and cardioprotection in perspective. Nat Rev Cardiol. 2020;17:773-89.
2. Imbesi A, Greco A, Spagnolo M, et al. Targeting inflammation after acute myocardial infarction. J Am Coll Cardiol. 2025;86:1146-69.
3. Nahrendorf M, Swirski FK. Innate immune cells in ischaemic heart disease: does myocardial infarction beget myocardial infarction? Eur Heart J. 2016;37:868-72.
4. Swann JW, Olson OC, Passegué E. Made to order: emergency myelopoiesis and demand-adapted innate immune cell production. Nat Rev Immunol. 2024;24:596-613.
5. Buntsma N, van der Pol E, Nieuwland R, Gąsecka A. Extracellular Vesicles in Coronary Artery Disease. In: Xiao J, Editor. Extracellular vesicles in cardiovascular and metabolic diseases. Singapore: Springer Nature; 2023. pp. 81-103.
6. Ohayon-Steckel L, Zhang X, Haque S, et al. miR-499 in platelet-derived extracellular vesicles augments inflammatory cell generation and cardiac remodeling after myocardial infarction. Circulation. 2026;153:243-59.
7. Cai Z, Xie Q, Hu T, et al. S100A8/A9 in myocardial infarction: a promising biomarker and therapeutic target. Front Cell Dev Biol. 2020;8:603902.
8. Adachi T, Nakanishi M, Otsuka Y, et al. Plasma microRNA 499 as a biomarker of acute myocardial infarction. Clin Chem. 2010;56:1183-5.
9. Hu Z, Li W, Wei L, Ma J. Lactoferrin in cancer: focus on mechanisms and translational medicine. Biochim Biophys Acta Rev Cancer. 2025;1880:189330.
10. Boulanger CM, Loyer X, Rautou PE, Amabile N. Extracellular vesicles in coronary artery disease. Nat Rev Cardiol. 2017;14:259-72.
11. Ma Y, Dong S, Grippin AJ, et al. Engineering therapeutical extracellular vesicles for clinical translation. Trends Biotechnol. 2025;43:61-82.
